A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm safety and efficacy of its ADHD therapeutic on a more real-world population, since phases I-III included more narrow inclusion/exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm safety and efficacy of its ADHD therapeutic on a more real-world population, since phases I-III included more narrow inclusion/exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm safety and efficacy of its ADHD therapeutic on a more real-world population, since phases I-III included more narrow inclusion/exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm safety and efficacy of its ADHD therapeutic on a more real-world population, since phases I-III included more narrow inclusion/exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm safety and efficacy of its ADHD therapeutic on a more real-world population, since phases I-III included more narrow inclusion/exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm safety and efficacy of its ADHD therapeutic on a more real-world population, since phases I-III included more narrow inclusion/exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm the safety and efficacy of its ADHD therapeutic on a more real-world population. Phases I-III included narrow inclusion and exclusion criteria.
A biopharmaceutical company is seeking a Phase IV clinical trial to confirm safety and efficacy of its ADHD therapeutic on a more real-world population, since phases I-III included more narrow inclusion/exclusion criteria.
A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.
Medical device company, Mi-Helper, Inc., needed to find participants with a specific type of migraine. This required a long run-in period and mitigation to reduce the risk of drop-off before participants reached active treatment. In addition, Mi-Helper needed to ensure participants used the at-home device properly.